Tabula Rasa HealthCare (NASDAQ:TRHC) Downgraded by ValuEngine

Tabula Rasa HealthCare (NASDAQ:TRHC) was downgraded by stock analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research report issued on Wednesday, ValuEngine reports.

A number of other research analysts have also issued reports on TRHC. Zacks Investment Research lowered shares of Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research report on Saturday. Cantor Fitzgerald decreased their target price on shares of Tabula Rasa HealthCare from $99.00 to $85.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. BidaskClub lowered shares of Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research report on Friday, October 11th. Stifel Nicolaus upgraded shares of Tabula Rasa HealthCare from a “hold” rating to a “buy” rating and increased their target price for the stock from $50.00 to $75.00 in a research report on Friday, August 30th. Finally, Piper Jaffray Companies decreased their target price on shares of Tabula Rasa HealthCare from $78.00 to $66.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $71.54.

Shares of NASDAQ:TRHC opened at $41.01 on Wednesday. The company’s 50 day moving average price is $51.43 and its two-hundred day moving average price is $52.78. Tabula Rasa HealthCare has a 12-month low of $40.06 and a 12-month high of $78.20. The firm has a market cap of $1.01 billion, a PE ratio of 120.62 and a beta of 1.62. The company has a quick ratio of 2.13, a current ratio of 2.22 and a debt-to-equity ratio of 1.32.

In related news, President Orsula V. Knowlton sold 8,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $56.05, for a total transaction of $448,400.00. Also, CFO Brian W. Adams sold 2,000 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $60.00, for a total transaction of $120,000.00. Following the sale, the chief financial officer now owns 198,037 shares in the company, valued at approximately $11,882,220. The disclosure for this sale can be found here. Insiders have sold a total of 72,000 shares of company stock worth $4,032,090 in the last quarter. 11.80% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Lisanti Capital Growth LLC boosted its position in shares of Tabula Rasa HealthCare by 116.4% during the 3rd quarter. Lisanti Capital Growth LLC now owns 67,420 shares of the company’s stock worth $3,704,000 after acquiring an additional 36,265 shares in the last quarter. Mason Street Advisors LLC lifted its stake in Tabula Rasa HealthCare by 9.6% in the 3rd quarter. Mason Street Advisors LLC now owns 6,675 shares of the company’s stock valued at $367,000 after purchasing an additional 583 shares during the last quarter. First Mercantile Trust Co. lifted its stake in Tabula Rasa HealthCare by 137.0% in the 3rd quarter. First Mercantile Trust Co. now owns 2,837 shares of the company’s stock valued at $155,000 after purchasing an additional 1,640 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in Tabula Rasa HealthCare by 939.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 188,480 shares of the company’s stock valued at $10,355,000 after purchasing an additional 170,345 shares during the last quarter. Finally, BB&T Corp bought a new position in Tabula Rasa HealthCare in the 3rd quarter valued at approximately $203,000. Institutional investors and hedge funds own 99.58% of the company’s stock.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

See Also: What is quantitative easing?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.